Physiomics PLC - oncology consultant - Reports revenue of GBP799,055 in financial year to June 30, up from GBP718,965 year prior. Pretax loss slims to GBP133,706 from GBP200,749. Says business development pipeline is the "strongest it has ever been".
"The company expects to continue to attract both repeat business and new clients of all sizes, to develop its personalised dosing technology and to explore innovative collaboration opportunities over the course of the current financial year," says Physiomics.
Current stock price: 7.57 pence
Year-to-date change: more than doubled from 3.45p at end of 2019
By Lucy Heming;Â firstname.lastname@example.org
Copyright 2020 Alliance News Limited. All Rights Reserved.